Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 6.05%
As of Friday, November 13, Galectin Therapeutics Inc.’s GALT share price has dipped by 6.05%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Cynthia McLaughlin
Jenna Brashear
Jenna Brashear
| Share Statistics | GALT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $271.4 | $203.5 | 32% |
|
| Shares Out (Mil) | 89.6 | 55.2 | 59% |
|
| Institutional Ownership | 25.7% | 93.3% | 11% |
|
| Float (Mil) | 47.9 | 40.4 | 45% |
|
| Beta | 0.50 | 1.05 | 27% |
|
| Avg Daily Volume (000s) | 210 | 569 | 45% |
|
| Price Change (52-week) |
(53.1%) | 38.8% | 20% |
|
| Growth | GALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (5.6%) | (10.7%) | 33% |
|
| EPS (5yr) | (3.2%) | 15.4% | 27 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.1% | (15.7%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($44) | 22% |
|
| EPS (TTM) | ($0.327) | ($1.400) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($35) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $334 | $142 | 31% |
|
| Valuation | GALT | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.96 | na |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GALT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (179.3%) | (47.0%) | 2% |
|
| ROE | 28.7% | (51.8%) | 86% |
|
| Liabilities to Assets | 357.0% | 29.6% | 100% |
|
| F-Score | 2 | 3 | 7% |
|
Galectin Therapeutics Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors